Hormone Resistance in Breast Cancer

Alaa Kandil

Professor of Clinical Oncology, Alexandria School of Medicine

Corresponding Author: Alaa Kandil  E-mail: alaakandil@hotmail.com

Hormonal therapy is one of the oldest known breast cancer treatments, being also known as an early form of targeted therapy. Hormone receptors (estrogen (ER) & progesterone(PR)) are usually expressed in 60-70% of breast cancer patients1.

Unfortunately, with the use of all available hormonal therapy agents, resistance to such treatment occurs in a substantial percentage of patients and that applies to early stage and metastatic disease.

Recent evidence suggests that common molecular adaptations occur during resistance to hormonal therapy agents that use various signal transduction pathways, often involving cross-talk with a retained and functional estrogen receptor (ER) protein. This cross-talk appears to take place at different levels2.

Extensive research has been focusing on the problem of hormone resistance trying to understand the underlying molecular mechanisms and identifying cellular pathways that are responsible for hormone resistance.

THE PROTO-ONCOGENE HER-2/neu (erbB-2) encodes a 185-kd transmembrane glycoprotein and is a member of the epidermal growth factor receptor family3. Preclinical studies have suggested that estrogen-dependent cultured human breast cancer cell lines are rendered hormone independent after transfection with multiple copies of the stably expressed HER-2/neu gene4-6.

Retrospective metastatic and adjuvant clinical studies in estrogen receptor (ER)-positive breast cancers have addressed this issue. Some have suggested that HER-2/neu overexpression is associated with hormone resistance7-9, whereas others have found no such association10-12.

On the same line, looking into more cellular pathways, in a subset of 114 hormone–responsive-breast-cancer-patients treated with neoadjuvant letrozole alone or combined with metronomic cyclophosphamide, Generali et al.13 reported that ERα form was an independent factor for sensitivity to chemoendocrine treatment, whereas HIF-1α (hypoxia-inducible factor 1α) and p44/42 MAPK (mitogen-activated protein kinase) were independent factors for resistance. These findings have clear potential implications for future strategies in the management of clinical trials with aromatase inhibitors in the management of breast cancer13.

Recently, Phosphatidyl inositol 3-kinase (PI3K) pathway was identified as an important pathway in breast cancer, also found to be frequently altered with both amplifications and mutations in its encoding genes. PI3K pathway plays a major role in different cellular functions related to cell growth, proliferation and antiapoptosis. AKT is a serine/threonine kinase that has been demonstrated to play an important role in survival when cells are exposed to different apoptotic stimuli. Recent studies show that aberrant activation of AKT in breast carcinoma is associated with a poor prognosis and resistance to endocrine therapy and chemotherapy14,15.

mTOR (mammalian target of rapamycin) is the effector of the PI3K/AKT pathway, activation of mTOR results in phosphorylation of its own effectors (Fig. 1), the best studied of which are eukaryotic initiation factor 4E-binding protein1(4E-BP1) and S6 kinase1(S6K1) which is a key regulator of cell growth. S6K1 phosphorylates important cellular targets, including insulin receptor substrate 1 (IRS-1), eukaryotic elongation factor-2 kinase, mTOR, glycogen synthase kinase 3, and S6K1 Aly/REF-like target16.

The story started with the discovery of rapamycin that took place in 1975 on the island of Rapa Nui, from which it derives its name. Initially developed as an antibiotic, it was noted that rapamycin possesses antiproliferative properties, especially
against lymphocytes. Thus, the agent was studied as an immunosuppressive and eventually approved for prophylaxis of renal allograft rejection. In 1991, the target of rapamycin was discovered in yeast and named target of rapamycin (TOR)\textsuperscript{17}. The only known homolog in mammals was subsequently cloned and called mammalian target of rapamycin, or mTOR\textsuperscript{18}. 

![Figure 1: PI3K/AKT/mTOR pathway.](image1)

Most recently, we have three rapamycin analogs in cancer clinical trials: temsirolimus, everolimus, and deforolimus. They have efficacy in a wide range of malignancies including breast cancer, renal cell carcinoma (RCC), sarcoma, lymphoma, leukemia, glioblastoma, endometrial carcinoma, and neuroendocrine carcinomas.

In the GINECO phase II study\textsuperscript{19}, postmenopausal breast cancer (hormone positive, Her-2-neu negative) patients with proven AI (Aromatase inhibitor) resistant/progressive disease showed a 55% reduction in the risk of death when they were treated with the combination of tamoxifen plus everolimus(TAMRAD) when compared to tamoxifen alone. Also patients who received everolimus had better clinical benefit rate, time to progression and overall survival (Fig. 2).

More exciting data were recently reported in a phase III trial (BOLERO2) by Baselga et al.\textsuperscript{20}. In this trial, the combination of everolimus plus the steroidal aromatase inhibitor exemestane was used against exemestane alone in hormone responsive, Her-2 negative breast cancer patients (N=724) who progressed on non steroidal aromatase inhibitor therapy. The results showed a significantly better PFS in patients receiving the combination compared to exemestane alone (median 6.9 months vs 2.8 months, \(P=0.001\)), corresponding to a hazard ratio reduction of 57% (Fig. 3).

![Figure 2: GINECO results of PFS & OS.](image2)

![Figure 3: Kaplan–Meier Plot of Progression-free Survival (BOLER2).](image3)
The magnitude of benefit seen with this combination, considering the limited treatment options left for this subgroup of patients, is quite acceptable. Still, the benefits reported should be weighed against the increased side effects (mainly stomatitis, fatigue and diarrhea) observed with the combination.

Further research is needed to identify the subset of patients who would benefit the most of this combination oral therapy. More importantly is to look into the type of hormone resistance, being primary or secondary. Another great deal of work is needed in the area of combination with other targeted therapies so as to make the most of the mTOR inhibitors in a larger subsets of breast cancer patients.

REFERENCES